GLUE Monte Rosa Therapeutics, Inc.
Price Chart
Executive Summary
Monte Rosa Therapeutics announced a supply agreement with Johnson & Johnson to evaluate its investigational drug MRT-2359 in combination with ERLEADA® (apalutamide) in a planned Phase 2 study for metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations, expected to initiate in Q3 2026. The decision follows encouraging early clinical activity observed in a Phase 1/2 trial combining MRT-2359 with enzalutamide in heavily pretreated patients.
Actionable Insight
Watch for interim data from the upcoming Phase 2 trial in 2026–2027; the combination's safety and efficacy in AR-mutant mCRPC could validate Monte Rosa’s molecular glue platform and drive partnership or licensing interest. However, lack of near-term monetization and high development risk remain concerns.
Key Facts
- Monte Rosa will sponsor and conduct a Phase 2 study of MRT-2359 in combination with Johnson & Johnson's ERLEADA® in AR-mutant mCRPC patients, expected to start in Q3 2026.
- The study will enroll up to 25 patients and assess PSA response, RECIST response, duration of response, PFS, rPFS, and safety.
- Positive early data from an ongoing Phase 1/2 study of MRT-2359 + enzalutamide were presented at ASCO GU 2026.
- Johnson & Johnson will supply ERLEADA®; no financial terms of the agreement were disclosed.
- MRT-2359 is a GSPT1-directed molecular glue degrader targeting MYC-driven cancers, including prostate cancer.
Financial Impact
No direct financial impact disclosed; potential long-term value if clinical activity is confirmed and program advances to registrational trials.
Risk Factors
- Clinical development risk: MRT-2359 remains early-stage; failure in Phase 2 would significantly devalue the program.
- Combination safety risk: ERLEADA® has known risks including fractures, falls, seizures, and severe skin reactions, which could complicate tolerability.
- Dilution risk: Monte Rosa may require future capital raises to fund development, potentially diluting shareholders.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256118 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $17.59 $17.36 | ▼ −1.31% | ▼ −1.71% | $18.24 (+3.67%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $17.59 $17.36 | ▼ −1.31% | ▼ −1.71% | $18.24 (+3.67%) |
|
Jun 1, 2026
13d ago
|
Insider Cluster
| $17.74 $17.59 | ▼ −0.85% | ▼ −0.15% | $18.24 (+2.79%) |
|
May 7, 2026
5w ago
|
8-K
| $19.81 $19.39 | ▼ −2.12% | ▼ −2.95% | $18.24 (−7.95%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $19.81 $20.89 | ▲ +5.45% | ▲ +6.11% | $18.24 (−7.95%) |
|
Apr 9, 2026
9w ago
|
Insider Cluster
| $18.05 $17.48 | ▼ −3.16% | ▼ −3.10% | $18.24 (+1.02%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $16.03 $15.76 | ▼ −1.68% | ▼ −0.29% | $18.24 (+13.76%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $16.35 $16.03 | ▼ −1.96% | ▼ −2.23% | $18.24 (+11.53%) |
|
Mar 2, 2026
15w ago
|
Insider Cluster
| $18.50 $17.96 | ▼ −2.92% | ▼ −2.00% | $18.24 (−1.43%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $18.50 $17.96 | ▼ −2.92% | ▼ −2.00% | $18.24 (−1.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access